Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Library Location
Language
Publication DateAtherosclerosis, ISSN 0021-9150, 2010, Volume 211, Issue 2, pp. 353 - 360
Abstract Increased Very Low Density Lipoprotein (VLDL) production is a major feature of diabetic dyslipidemia with consequences on the metabolism of other...
Cardiovascular | Type 2 | Triglycerides | Diabetes | Lipogenesis | Insulin | VLDL | TRIGLYCERIDE TRANSFER PROTEIN | FED HAMSTER MODEL | DE-NOVO LIPOGENESIS | LOW-DENSITY LIPOPROTEIN | ELEMENT-BINDING PROTEIN | ENDOPLASMIC-RETICULUM STRESS | ADP-RIBOSYLATION FACTOR-1 | CULTURED RAT HEPATOCYTES | FATTY-ACID OXIDATION | INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | Apolipoproteins B - metabolism | Humans | Liver - metabolism | Gene Expression Regulation | Insulin Resistance | Diabetes Mellitus, Type 2 - metabolism | Hepatocytes - metabolism | Triglycerides - metabolism | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Animals | Models, Biological | Lipoproteins, VLDL - metabolism | Atherosclerosis | Adiponectin - metabolism | Lipoproteins, LDL - metabolism | Type 2 diabetes | Hyperglycemia | Low density lipoproteins | Physiological aspects | Insulin resistance | Blood lipids | Protein binding
Cardiovascular | Type 2 | Triglycerides | Diabetes | Lipogenesis | Insulin | VLDL | TRIGLYCERIDE TRANSFER PROTEIN | FED HAMSTER MODEL | DE-NOVO LIPOGENESIS | LOW-DENSITY LIPOPROTEIN | ELEMENT-BINDING PROTEIN | ENDOPLASMIC-RETICULUM STRESS | ADP-RIBOSYLATION FACTOR-1 | CULTURED RAT HEPATOCYTES | FATTY-ACID OXIDATION | INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | Apolipoproteins B - metabolism | Humans | Liver - metabolism | Gene Expression Regulation | Insulin Resistance | Diabetes Mellitus, Type 2 - metabolism | Hepatocytes - metabolism | Triglycerides - metabolism | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Animals | Models, Biological | Lipoproteins, VLDL - metabolism | Atherosclerosis | Adiponectin - metabolism | Lipoproteins, LDL - metabolism | Type 2 diabetes | Hyperglycemia | Low density lipoproteins | Physiological aspects | Insulin resistance | Blood lipids | Protein binding
Journal Article
Details 
Digital rights
Loading Rights
2.
Full Text
The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism
Journal of Lipid Research, ISSN 0022-2275, 04/2009, Volume 50, Issue Supplement, pp. S162 - S166
Apolipoprotein B (apoB) is the essential protein required for the assembly and secretion of chylomicrons from the small intestine and VLDLs from the liver....
Lipids | Lipoproteins | Liver | TRIGLYCERIDE TRANSFER PROTEIN | lipids | RAT HEPATOCYTES | liver | DENSITY LIPOPROTEIN OVERPRODUCTION | PROTEASOMAL DEGRADATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MEMBRANE-PROTEIN | ENDOPLASMIC-RETICULUM STRESS | INTRACELLULAR DEGRADATION | QUALITY-CONTROL | INSULIN-RESISTANCE | HEP G2 CELLS | lipoproteins | Endoplasmic Reticulum - metabolism | Apolipoproteins B - metabolism | Insulin - metabolism | Biological Transport | Fatty Acids - metabolism | Humans | Lipoprotein Metabolism
Lipids | Lipoproteins | Liver | TRIGLYCERIDE TRANSFER PROTEIN | lipids | RAT HEPATOCYTES | liver | DENSITY LIPOPROTEIN OVERPRODUCTION | PROTEASOMAL DEGRADATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MEMBRANE-PROTEIN | ENDOPLASMIC-RETICULUM STRESS | INTRACELLULAR DEGRADATION | QUALITY-CONTROL | INSULIN-RESISTANCE | HEP G2 CELLS | lipoproteins | Endoplasmic Reticulum - metabolism | Apolipoproteins B - metabolism | Insulin - metabolism | Biological Transport | Fatty Acids - metabolism | Humans | Lipoprotein Metabolism
Journal Article
Details
Digital rights
Loading RightsNature Reviews Endocrinology, ISSN 1759-5029, 08/2016, Volume 12, Issue 8, pp. 467 - 484
Familial hypercholesterolaemia, familial combined hyperlipidaemia (FCH) and elevated lipoprotein(a) are common, inherited disorders of apolipoprotein B...
TRIAL ATHEROTHROMBOSIS INTERVENTION | LDL-CHOLESTEROL | AMERICAN-DIABETES-ASSOCIATION | TRANSFER PROTEIN INHIBITOR | FAMILIAL-COMBINED HYPERLIPIDEMIA | NON-HDL CHOLESTEROL | ENDOCRINOLOGY & METABOLISM | SUBTILISIN/KEXIN TYPE 9 | LIPID-LOWERING THERAPY | CORONARY-ARTERY-DISEASE | DENSITY-LIPOPROTEIN RECEPTOR | Hyperlipoproteinemia Type II - complications | Severity of Illness Index | Hyperlipoproteinemia Type II - therapy | Apolipoproteins B - metabolism | Life Style | Hyperlipidemia, Familial Combined - complications | Hyperlipidemia, Familial Combined - metabolism | Risk Assessment | Risk Reduction Behavior | Humans | Male | Combined Modality Therapy | Hyperlipoproteinemia Type II - metabolism | Hyperlipidemia, Familial Combined - therapy | Female | Atherosclerosis - prevention & control | Care and treatment | Hypercholesterolemia | Physiological aspects | Development and progression | Genetic aspects | Diagnosis | Research | Apolipoproteins
TRIAL ATHEROTHROMBOSIS INTERVENTION | LDL-CHOLESTEROL | AMERICAN-DIABETES-ASSOCIATION | TRANSFER PROTEIN INHIBITOR | FAMILIAL-COMBINED HYPERLIPIDEMIA | NON-HDL CHOLESTEROL | ENDOCRINOLOGY & METABOLISM | SUBTILISIN/KEXIN TYPE 9 | LIPID-LOWERING THERAPY | CORONARY-ARTERY-DISEASE | DENSITY-LIPOPROTEIN RECEPTOR | Hyperlipoproteinemia Type II - complications | Severity of Illness Index | Hyperlipoproteinemia Type II - therapy | Apolipoproteins B - metabolism | Life Style | Hyperlipidemia, Familial Combined - complications | Hyperlipidemia, Familial Combined - metabolism | Risk Assessment | Risk Reduction Behavior | Humans | Male | Combined Modality Therapy | Hyperlipoproteinemia Type II - metabolism | Hyperlipidemia, Familial Combined - therapy | Female | Atherosclerosis - prevention & control | Care and treatment | Hypercholesterolemia | Physiological aspects | Development and progression | Genetic aspects | Diagnosis | Research | Apolipoproteins
Journal Article
Details
Digital rights
Loading RightsEuropean Journal of Clinical Investigation, ISSN 0014-2972, 02/2019, Volume 49, Issue 2, pp. e13053 - n/a
Background Lipoprotein apheresis effectively lowers lipoprotein(a) [Lp(a)] and low‐density lipoprotein (LDL) by approximately 60%‐70%. The rebound of LDL and...
LDL-APHERESIS | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | CATABOLISM | THERAPY | CHOLESTEROL | KINETICS | LIPID APHERESIS | RECEPTOR | RISK | LP(A) | Apolipoproteins B - metabolism | Hypercholesterolemia - blood | Cross-Sectional Studies | Humans | Middle Aged | Male | Blood Component Removal | Coronary Artery Disease - blood | Fish Oils - therapeutic use | Young Adult | Anticholesteremic Agents - therapeutic use | Coronary Artery Disease - therapy | Coronary Artery Disease - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Adult | Female | Hypercholesterolemia - complications | Aged | Aspirin - therapeutic use | Ezetimibe - therapeutic use | Lipoproteins, LDL - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Lipoprotein(a) - metabolism | Medical research | Care and treatment | Low density lipoproteins | Analysis | Physiological aspects | Medicine, Experimental | Blood lipids | Apolipoproteins | Coronary heart disease | Lipoprotein A | Lipoproteins (low density) | Apheresis | Coronary artery | Cardiovascular disease | Metabolism | Coronary artery disease | Patients | Density | Apolipoprotein B | Lipoproteins | Arteriosclerosis | Coronary vessels | Atherosclerosis | Catabolism | Metabolic pathways | Kinetics | Lipid metabolism | Cardiovascular diseases | Heart diseases
LDL-APHERESIS | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | CATABOLISM | THERAPY | CHOLESTEROL | KINETICS | LIPID APHERESIS | RECEPTOR | RISK | LP(A) | Apolipoproteins B - metabolism | Hypercholesterolemia - blood | Cross-Sectional Studies | Humans | Middle Aged | Male | Blood Component Removal | Coronary Artery Disease - blood | Fish Oils - therapeutic use | Young Adult | Anticholesteremic Agents - therapeutic use | Coronary Artery Disease - therapy | Coronary Artery Disease - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Adult | Female | Hypercholesterolemia - complications | Aged | Aspirin - therapeutic use | Ezetimibe - therapeutic use | Lipoproteins, LDL - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Lipoprotein(a) - metabolism | Medical research | Care and treatment | Low density lipoproteins | Analysis | Physiological aspects | Medicine, Experimental | Blood lipids | Apolipoproteins | Coronary heart disease | Lipoprotein A | Lipoproteins (low density) | Apheresis | Coronary artery | Cardiovascular disease | Metabolism | Coronary artery disease | Patients | Density | Apolipoprotein B | Lipoproteins | Arteriosclerosis | Coronary vessels | Atherosclerosis | Catabolism | Metabolic pathways | Kinetics | Lipid metabolism | Cardiovascular diseases | Heart diseases
Journal Article
Details
Digital rights
Loading RightsArteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 12/1997, Volume 17, Issue 12, pp. 3542 - 3556
The apolipoprotein B containing lipoproteins VLDL, IDL, and LDL exhibit variation in their structure, function, and metabolism. These major lipoprotein classes...
Plasma triglyceride | Small, dense LDL | Lipoprotein lipase | Kinetics | VLDL | Hepatic lipase | CORONARY-ARTERY DISEASE | FAMILIAL HYPERCHOLESTEROLEMIA | small dense LDL | hepatic lipase | LOW-DENSITY-LIPOPROTEIN | CHOLESTERYL ESTER TRANSFER | HEPATIC LIPASE DEFICIENCY | TRIGLYCERIDE-RICH LIPOPROTEINS | VERY-LOW-DENSITY | LDL SUBCLASS PHENOTYPES | NORMAL HUMAN-PLASMA | plasma triglyceride | lipoprotein lipase | PERIPHERAL VASCULAR DISEASE | kinetics | HEMATOLOGY | TRANSFER PROTEIN-DEFICIENCY
Plasma triglyceride | Small, dense LDL | Lipoprotein lipase | Kinetics | VLDL | Hepatic lipase | CORONARY-ARTERY DISEASE | FAMILIAL HYPERCHOLESTEROLEMIA | small dense LDL | hepatic lipase | LOW-DENSITY-LIPOPROTEIN | CHOLESTERYL ESTER TRANSFER | HEPATIC LIPASE DEFICIENCY | TRIGLYCERIDE-RICH LIPOPROTEINS | VERY-LOW-DENSITY | LDL SUBCLASS PHENOTYPES | NORMAL HUMAN-PLASMA | plasma triglyceride | lipoprotein lipase | PERIPHERAL VASCULAR DISEASE | kinetics | HEMATOLOGY | TRANSFER PROTEIN-DEFICIENCY
Journal Article
Details
Digital rights
Loading RightsJournal of Lipid Research, ISSN 0022-2275, 07/2009, Volume 50, Issue 7, pp. 1463 - 1471
Sixteen hyperlipidemic men were enrolled in a randomized, placebo-controlled, double-blind, cross-over study to evaluate the effect of ezetimibe 10 mg and...
Kinetic | Gas chromatography/mass spectrometry | Intestine | Liver | Cholesterol absorption and synthesis | Apolipoprotein B-100 | Apolipoprotein B-48 | LOVASTATIN | gas chromatography/mass spectrometry | FAMILIAL HYPERCHOLESTEROLEMIA | intestine | liver | BIOCHEMISTRY & MOLECULAR BIOLOGY | cholesterol absorption and synthesis | LOW-DENSITY-LIPOPROTEIN | VERY-LOW-DENSITY | ATORVASTATIN | apolipoprotein B-100 | PLASMA | KINETICS | CHOLESTEROL ABSORPTION INHIBITOR | PRAVASTATIN | kinetic | NONCHOLESTEROL STEROLS | Simvastatin - therapeutic use | Apolipoproteins B - metabolism | Double-Blind Method | Hyperlipidemias - metabolism | Humans | Hyperlipidemias - drug therapy | Ezetimibe | Male | Treatment Outcome | Lipoproteins - blood | Cross-Over Studies | Placebos - therapeutic use | Animals | Anticholesteremic Agents - therapeutic use | Azetidines - therapeutic use | Triglycerides - blood | Adult | Cholesterol, LDL - blood | Drug Therapy, Combination | Hyperlipidemias - physiopathology | Patient-Oriented and Epidemiological Research | mass spectrometry | gas chromatography
Kinetic | Gas chromatography/mass spectrometry | Intestine | Liver | Cholesterol absorption and synthesis | Apolipoprotein B-100 | Apolipoprotein B-48 | LOVASTATIN | gas chromatography/mass spectrometry | FAMILIAL HYPERCHOLESTEROLEMIA | intestine | liver | BIOCHEMISTRY & MOLECULAR BIOLOGY | cholesterol absorption and synthesis | LOW-DENSITY-LIPOPROTEIN | VERY-LOW-DENSITY | ATORVASTATIN | apolipoprotein B-100 | PLASMA | KINETICS | CHOLESTEROL ABSORPTION INHIBITOR | PRAVASTATIN | kinetic | NONCHOLESTEROL STEROLS | Simvastatin - therapeutic use | Apolipoproteins B - metabolism | Double-Blind Method | Hyperlipidemias - metabolism | Humans | Hyperlipidemias - drug therapy | Ezetimibe | Male | Treatment Outcome | Lipoproteins - blood | Cross-Over Studies | Placebos - therapeutic use | Animals | Anticholesteremic Agents - therapeutic use | Azetidines - therapeutic use | Triglycerides - blood | Adult | Cholesterol, LDL - blood | Drug Therapy, Combination | Hyperlipidemias - physiopathology | Patient-Oriented and Epidemiological Research | mass spectrometry | gas chromatography
Journal Article
Details
Digital rights
Loading RightsCirculation, ISSN 0009-7322, 01/2017, Volume 135, Issue 4, pp. 363 - 365
PCSK9 protein, human | Editorials | lipoproteins | TRIGLYCERIDE | CARDIAC & CARDIOVASCULAR SYSTEMS | PCSK9 | PERIPHERAL VASCULAR DISEASE | MEDIATED REDUCTION | EVOLOCUMAB | Cholesterol, LDL | Proprotein Convertases | Apolipoproteins B | Subtilisins | Receptors, LDL | Proprotein Convertase 9 | Protein metabolism | Research | Cardiovascular diseases | Apolipoproteins | Risk factors
Journal Article
Details
Digital rights
Loading RightsCirculation Research, ISSN 0009-7330, 01/2014, Volume 114, Issue 1, pp. 32 - 40
RATIONALE:Activated nuclear factor (NF)-κB signaling in the vascular endothelium promotes the initiation and progression of atherosclerosis. Targeting...
atherosclerosis | microRNAs | NF-κB | endothelial cells | karyopherins | inflammation | SIGNALING PATHWAYS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHOSPHORYLATION | NF-B | ALPHA | MODEL | MAJOR ROLE | MIR-181A | LESIONS | E-KNOCKOUT MICE | ENDOTHELIAL-CELLS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | MicroRNAs - therapeutic use | Human Umbilical Vein Endothelial Cells - metabolism | Humans | Diet, High-Fat - adverse effects | MicroRNAs - metabolism | NF-kappa B - metabolism | Aorta - metabolism | Atherosclerosis - etiology | Inflammation - metabolism | Atherosclerosis - therapy | Atherosclerosis - pathology | NF-kappa B - antagonists & inhibitors | MicroRNAs - administration & dosage | Mice, Inbred C57BL | CD4-Positive T-Lymphocytes - metabolism | Atherosclerosis - metabolism | Aorta - pathology | Tunica Intima - metabolism | Macrophages - metabolism | Animals | Karyopherins - metabolism | Tunica Intima - pathology | Apolipoproteins E - genetics | Karyopherins - genetics | Mice | MicroRNAs - blood
atherosclerosis | microRNAs | NF-κB | endothelial cells | karyopherins | inflammation | SIGNALING PATHWAYS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHOSPHORYLATION | NF-B | ALPHA | MODEL | MAJOR ROLE | MIR-181A | LESIONS | E-KNOCKOUT MICE | ENDOTHELIAL-CELLS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | MicroRNAs - therapeutic use | Human Umbilical Vein Endothelial Cells - metabolism | Humans | Diet, High-Fat - adverse effects | MicroRNAs - metabolism | NF-kappa B - metabolism | Aorta - metabolism | Atherosclerosis - etiology | Inflammation - metabolism | Atherosclerosis - therapy | Atherosclerosis - pathology | NF-kappa B - antagonists & inhibitors | MicroRNAs - administration & dosage | Mice, Inbred C57BL | CD4-Positive T-Lymphocytes - metabolism | Atherosclerosis - metabolism | Aorta - pathology | Tunica Intima - metabolism | Macrophages - metabolism | Animals | Karyopherins - metabolism | Tunica Intima - pathology | Apolipoproteins E - genetics | Karyopherins - genetics | Mice | MicroRNAs - blood
Journal Article
Details
Digital rights
Loading RightsCritical Reviews in Clinical Laboratory Sciences, ISSN 1040-8363, 2005, Volume 42, Issue 5-6, pp. 515 - 545
The study of apolipoprotein (apo) B metabolism is central to our understanding of human lipoprotein metabolism. Moreover, the assembly and secretion of...
mouse models | molecular mechanisms | genetics | regulation | very low-density lipoprotein | cholesterol | microsomal triglyceride transfer protein | fatty liver | abetalipoproteinaemia | familial hypobetalipoproteinaemia | low-density lipoprotein | Low-density lipoprotein | Fatty liver | Mouse models | Very low-density lipoprotein | Familial hypobetalipoproteinaemia | Molecular mechanisms | Microsomal triglyceride transfer protein | Genetics | Regulation | Abetalipoproteinaemia | Cholesterol | APOBEC-1 COMPLEMENTATION FACTOR | LOW-DENSITY-LIPOPROTEIN | HOMOZYGOUS FAMILIAL HYPOBETALIPOPROTEINEMIA | TRIACYLGLYCEROL TRANSFER PROTEIN | PROTEOGLYCAN-BINDING-SITE | CARNITINE PALMITOYLTRANSFERASE I | TRIGLYCERIDE-TRANSFER-PROTEIN | RNA EDITING ENZYME | POLYMERASE CHAIN-REACTION | MEDICAL LABORATORY TECHNOLOGY | UBIQUITIN-PROTEASOME PATHWAY | Cholesterol, VLDL - secretion | Apolipoproteins B - metabolism | Abetalipoproteinemia - metabolism | Animals | Abetalipoproteinemia - genetics | Humans | Gene Expression Regulation | Apolipoproteins B - genetics | Apolipoproteins B - chemistry | Mutation - genetics | Cholesterol, VLDL - biosynthesis | Receptors, Lipoprotein - metabolism
mouse models | molecular mechanisms | genetics | regulation | very low-density lipoprotein | cholesterol | microsomal triglyceride transfer protein | fatty liver | abetalipoproteinaemia | familial hypobetalipoproteinaemia | low-density lipoprotein | Low-density lipoprotein | Fatty liver | Mouse models | Very low-density lipoprotein | Familial hypobetalipoproteinaemia | Molecular mechanisms | Microsomal triglyceride transfer protein | Genetics | Regulation | Abetalipoproteinaemia | Cholesterol | APOBEC-1 COMPLEMENTATION FACTOR | LOW-DENSITY-LIPOPROTEIN | HOMOZYGOUS FAMILIAL HYPOBETALIPOPROTEINEMIA | TRIACYLGLYCEROL TRANSFER PROTEIN | PROTEOGLYCAN-BINDING-SITE | CARNITINE PALMITOYLTRANSFERASE I | TRIGLYCERIDE-TRANSFER-PROTEIN | RNA EDITING ENZYME | POLYMERASE CHAIN-REACTION | MEDICAL LABORATORY TECHNOLOGY | UBIQUITIN-PROTEASOME PATHWAY | Cholesterol, VLDL - secretion | Apolipoproteins B - metabolism | Abetalipoproteinemia - metabolism | Animals | Abetalipoproteinemia - genetics | Humans | Gene Expression Regulation | Apolipoproteins B - genetics | Apolipoproteins B - chemistry | Mutation - genetics | Cholesterol, VLDL - biosynthesis | Receptors, Lipoprotein - metabolism
Journal Article
Details
Digital rights
Loading RightsCell Metabolism, ISSN 1550-4131, 07/2014, Volume 20, Issue 1, pp. 172 - 182
Oxysterols are cholesterol metabolites that serve multiple functions in lipid metabolism, including as liver X receptor (LXR) ligands. 27-hydroxycholesterol...
ADHESION | SIGNALING PATHWAYS | HEART-DISEASE | DNA-BINDING | LIVER X RECEPTORS | INFLAMMATION | TRANSCRIPTION | ENDOCRINOLOGY & METABOLISM | NF-KAPPA-B | INTERLEUKIN-6 GENE-EXPRESSION | STEROL 27-HYDROXYLASE | CELL BIOLOGY | Steroid Hydroxylases - metabolism | Apolipoproteins E - deficiency | JNK Mitogen-Activated Protein Kinases - metabolism | Male | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Apolipoproteins E - metabolism | Cytochrome P450 Family 7 | RNA Interference | Estrogen Receptor alpha - metabolism | Female | Cytokines - genetics | Steroid Hydroxylases - genetics | Macrophages - immunology | Cell Line | Atherosclerosis - pathology | NF-KappaB Inhibitor alpha | Cytokines - metabolism | Endothelial Cells - metabolism | Inflammation | Cell Adhesion - drug effects | Cholesterol - metabolism | Hydroxycholesterols - pharmacology | Atherosclerosis - metabolism | Mice, Knockout | Macrophages - metabolism | Animals | Estrogen Receptor alpha - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | Endothelial Cells - cytology | Apolipoproteins E - genetics | Steroid Hydroxylases - deficiency | Hydroxycholesterols - metabolism | Macrophages - drug effects | Mice | Endothelial Cells - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | RNA, Small Interfering - metabolism | Metabolites | Atherosclerosis | Estrogen | Cytochrome P-450 | Physiological aspects | Phenols | Cholesterol | Prevention | Blood circulation disorders | Liver | Endothelium
ADHESION | SIGNALING PATHWAYS | HEART-DISEASE | DNA-BINDING | LIVER X RECEPTORS | INFLAMMATION | TRANSCRIPTION | ENDOCRINOLOGY & METABOLISM | NF-KAPPA-B | INTERLEUKIN-6 GENE-EXPRESSION | STEROL 27-HYDROXYLASE | CELL BIOLOGY | Steroid Hydroxylases - metabolism | Apolipoproteins E - deficiency | JNK Mitogen-Activated Protein Kinases - metabolism | Male | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Apolipoproteins E - metabolism | Cytochrome P450 Family 7 | RNA Interference | Estrogen Receptor alpha - metabolism | Female | Cytokines - genetics | Steroid Hydroxylases - genetics | Macrophages - immunology | Cell Line | Atherosclerosis - pathology | NF-KappaB Inhibitor alpha | Cytokines - metabolism | Endothelial Cells - metabolism | Inflammation | Cell Adhesion - drug effects | Cholesterol - metabolism | Hydroxycholesterols - pharmacology | Atherosclerosis - metabolism | Mice, Knockout | Macrophages - metabolism | Animals | Estrogen Receptor alpha - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | Endothelial Cells - cytology | Apolipoproteins E - genetics | Steroid Hydroxylases - deficiency | Hydroxycholesterols - metabolism | Macrophages - drug effects | Mice | Endothelial Cells - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | RNA, Small Interfering - metabolism | Metabolites | Atherosclerosis | Estrogen | Cytochrome P-450 | Physiological aspects | Phenols | Cholesterol | Prevention | Blood circulation disorders | Liver | Endothelium
Journal Article
Details
Digital rights
Loading RightsNature, ISSN 0028-0836, 05/2012, Volume 485, Issue 7399, pp. 512 - 516
Human apolipoprotein E has three isoforms: APOE2, APOE3 and APOE4(1). APOE4 is a major genetic risk factor for Alzheimer's disease(2,3) and is associated with...
OXIDATIVE STRESS | DEMENTIA | PROTEIN | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | COGNITIVE IMPAIRMENT | NEURODEGENERATION | MICE | APOE | BLOOD-BRAIN-BARRIER | EXPRESSION | Neurons - pathology | Apolipoprotein E4 - genetics | Apolipoproteins E - deficiency | Cerebrovascular Circulation - physiology | Humans | Blood-Brain Barrier - physiopathology | NF-kappa B - metabolism | Apolipoproteins E - metabolism | Microcirculation | Matrix Metalloproteinase 9 - metabolism | Apolipoprotein E2 - deficiency | Apolipoprotein E4 - deficiency | Apolipoprotein E3 - deficiency | Blood-Brain Barrier - physiology | Neurons - metabolism | Cyclophilin A - metabolism | Apolipoprotein E4 - metabolism | Neurodegenerative Diseases - pathology | Apolipoprotein E2 - genetics | Pericytes - metabolism | Mice, Transgenic | Hippocampus - pathology | Neurodegenerative Diseases - metabolism | Apolipoprotein E3 - metabolism | Apolipoprotein E2 - metabolism | Blood-Brain Barrier - drug effects | Cyclophilin A - antagonists & inhibitors | Hippocampus - metabolism | Apolipoprotein E3 - genetics | Animals | Apolipoproteins E - genetics | Mice | Cyclophilin A - deficiency | Cyclophilin | Brain cells | Physiological aspects | Development and progression | Apolipoproteins | Properties | Alzheimer's disease | Proteins | Studies | Rodents
OXIDATIVE STRESS | DEMENTIA | PROTEIN | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | COGNITIVE IMPAIRMENT | NEURODEGENERATION | MICE | APOE | BLOOD-BRAIN-BARRIER | EXPRESSION | Neurons - pathology | Apolipoprotein E4 - genetics | Apolipoproteins E - deficiency | Cerebrovascular Circulation - physiology | Humans | Blood-Brain Barrier - physiopathology | NF-kappa B - metabolism | Apolipoproteins E - metabolism | Microcirculation | Matrix Metalloproteinase 9 - metabolism | Apolipoprotein E2 - deficiency | Apolipoprotein E4 - deficiency | Apolipoprotein E3 - deficiency | Blood-Brain Barrier - physiology | Neurons - metabolism | Cyclophilin A - metabolism | Apolipoprotein E4 - metabolism | Neurodegenerative Diseases - pathology | Apolipoprotein E2 - genetics | Pericytes - metabolism | Mice, Transgenic | Hippocampus - pathology | Neurodegenerative Diseases - metabolism | Apolipoprotein E3 - metabolism | Apolipoprotein E2 - metabolism | Blood-Brain Barrier - drug effects | Cyclophilin A - antagonists & inhibitors | Hippocampus - metabolism | Apolipoprotein E3 - genetics | Animals | Apolipoproteins E - genetics | Mice | Cyclophilin A - deficiency | Cyclophilin | Brain cells | Physiological aspects | Development and progression | Apolipoproteins | Properties | Alzheimer's disease | Proteins | Studies | Rodents
Journal Article
Details
Digital rights
Loading Rights